Second Clinic of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland.
Department of Health, Medicine, and Caring Sciences, Linköping University, Linköping, Sweden.
BMC Psychiatry. 2021 Feb 10;21(1):88. doi: 10.1186/s12888-021-03088-3.
Recurrence is a problem for many patients who have episodes of depression. In experimental settings, hyporeactivity in the Electrodermal Orienting Reactivity (EDOR) test has been observed to be more frequent in these patients. The aim of this study was to investigate the clinical value of this test with regard to a prognosis of episode recurrence in patients hospitalized for depression.
The study was performed using a cohort design at a specialized psychiatric clinic in Warsaw, Poland. The primary endpoint measure was relapse or recurrence of depression. Data on electrodermal reactivity measured by the EDOR test, clinical status, and psychiatric history were collected at the clinic. Relapse and recurrence data were collected by clinical interviews 1 year after the EDOR test. The predictive (adjusting for confounders) and comparative (relative to other predictors) performance of electrodermal hyporeactivity was assessed using simple and multiple binary logistic regression.
The patient sample included 97 patients aged between 20 and 81 years (mean, 51.2 years). Twenty patients (20.6%) were hyporeactive in the EDOR test. The group of hyporeactive patients did not differ significantly from the reactive group with regard to background factors or clinical status on admission. Forty-seven patients (51.6%) had at least one depressive episode during the follow-up period. In the analysis including potential confounders, the likelihood of relapse or recurrence of depression was nearly five times higher among the hyporeactive patients than the reactive patients (odds ratio [OR], 4.7; 95% confidence interval (CI), 1.3-16.2; p = 0.015). In the comparative analysis, only hyporeactivity was found to be associated with recurring episodes (OR, 3.3; 95% CI, 1.1-10.2; p = 0.036).
Electrodermal hyporeactivity was associated with a higher risk of relapse or recurrence after discharge among patients hospitalized for depression. This finding warrants further clinical investigations that cover different types of depression and account for causal mechanisms.
The study design was registered in the German Clinical Trials Register ( DRKS00010082 ).
许多经历过抑郁发作的患者都存在复发的问题。在实验环境中，电皮肤反应性（EDOR）测试中观察到的低反应性更为频繁。本研究旨在探讨该测试对住院抑郁症患者发作复发预后的临床价值。
该研究采用波兰华沙一家专门的精神病诊所的队列设计进行。主要终点是抑郁复发或复发。在诊所收集电皮肤反应性测量的 EDOR 测试、临床状态和精神病史的数据。在 EDOR 测试后 1 年通过临床访谈收集复发和复发数据。使用简单和多元二项逻辑回归评估电皮肤低反应性的预测（调整混杂因素）和比较（相对于其他预测因子）性能。
患者样本包括 97 名年龄在 20 至 81 岁之间（平均年龄为 51.2 岁）的患者。20 名患者（20.6%）在 EDOR 测试中反应性较低。反应性患者组与无反应性患者组在背景因素或入院时的临床状态方面无显著差异。47 名患者（51.6%）在随访期间至少发生过一次抑郁发作。在纳入潜在混杂因素的分析中，无反应性患者的抑郁复发或复发的可能性是反应性患者的近五倍（优势比 [OR]，4.7；95%置信区间 [CI]，1.3-16.2；p=0.015）。在比较分析中，只有低反应性与反复发作有关（OR，3.3；95% CI，1.1-10.2；p=0.036）。
电皮肤低反应性与住院抑郁症患者出院后复发或复发的风险增加相关。这一发现需要进一步的临床研究，涵盖不同类型的抑郁症，并考虑因果机制。
研究设计在德国临床试验注册处（DRKS00010082）注册。
